AIM ImmunoTech, Inc. (AIM)
Stock Price:
$2.99 USD
0.07 (2.40%)
Updated Aug 7, 2020 4:00 PM EDT - Market closed
Key Info
| Market Cap |
97.55M |
| Revenue (ttm) |
185,000 |
| Net Income (ttm) |
-9.97M |
| Shares Out |
32.62M |
| EPS (ttm) |
-5.87 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Aug 7, 2020 |
| Last Price |
$2.99 |
| Previous Close |
$2.92 |
| Change ($) |
0.07 |
| Change (%) |
2.40% |
| Day's Open |
2.87 |
| Day's Range |
2.82 - 3.10 |
| Day's Volume |
6,559,349 |
| 52-Week Range |
0.38 - 7.11 |
More Stats
| Market Cap |
97.55M |
| Enterprise Value |
76.06M |
| Earnings Date (est) |
Aug 17, 2020 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
32.62M |
| Float |
28.77M |
| EPS (basic) |
-0.63 |
| EPS (diluted) |
-5.87 |
| FCF / Share |
-0.61 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
2.40M |
| Short Ratio |
0.48 |
| Short % of Float |
7.47% |
| Beta |
-0.81 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
527.28 |
| PB Ratio |
2.77 |
| Revenue |
185,000 |
| Operating Income |
-12.84M |
| Net Income |
-9.97M |
| Free Cash Flow |
-10.73M |
| Net Cash |
21.48M |
| Net Cash / Share |
0.66 |
| Gross Margin |
-407.03% |
| Operating Margin |
-6,941.62% |
| Profit Margin |
-5,390.80% |
| FCF Margin |
-5,800.54% |
| ROA |
-27.33% |
| ROE |
-51.11% |
| ROIC |
-52.80% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (3)
| Buy |
3 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$6.17*
(106.35% upside)
Low
5.00
Current: $2.99
High
7.00
Target: 6.17
*Average 12-month price target from 3 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|
| Revenue | 0.14 | 0.37 | 0.44 | 0.09 | 0.13 | 0.20 | 0.15 | 0.21 | 0.16 | 0.14 |
| Revenue Growth | -61.85% | -16.02% | 375% | -30.83% | -32.49% | 31.33% | -29.58% | 32.3% | 19.26% | - |
| Gross Profit | -0.75 | -0.52 | -0.75 | -1.02 | -1.47 | -1.05 | -1.08 | -1.78 | -0.88 | -1.21 |
| Operating Income | -12.44 | -11.27 | -11.42 | -12.18 | -16.65 | -19.10 | -17.17 | -20.34 | -14.30 | -16.39 |
| Net Income | -9.53 | -9.83 | -8.26 | -7.50 | -15.23 | -17.45 | -16.23 | -17.35 | -9.02 | -13.14 |
| Shares Outstanding | 3.64 | 1.00 | 0.65 | 0.50 | 0.45 | 0.36 | 0.32 | 0.27 | 0.26 | 0.25 |
| Earnings Per Share | -2.62 | -9.77 | -12.76 | -14.96 | -33.88 | -48.83 | -52.80 | -63.36 | -36.96 | -52.80 |
| Operating Cash Flow | -9.07 | -10.64 | -7.94 | -7.38 | -16.05 | -13.96 | -16.90 | -13.14 | -10.10 | -11.89 |
| Capital Expenditures | -0.07 | 1.00 | -0.07 | -0.45 | -0.49 | -0.76 | -1.14 | -5.97 | -2.04 | -1.07 |
| Free Cash Flow | -9.14 | -9.64 | -8.01 | -7.83 | -16.54 | -14.73 | -18.04 | -19.10 | -12.13 | -12.95 |
| Cash & Equivalents | 8.78 | 1.83 | 2.11 | 5.87 | 8.91 | 16.11 | 18.19 | 43.95 | 30.36 | 35.61 |
| Total Debt | 6.38 | 5.93 | 1.84 | - | - | 0.02 | 0.06 | 0.10 | 0.15 | 0.16 |
| Net Cash / Debt | 2.40 | -4.10 | 0.27 | 5.87 | 8.91 | 16.09 | 18.14 | 43.85 | 30.21 | 35.45 |
| Assets | 20.22 | 13.85 | 14.21 | 18.87 | 22.80 | 29.44 | 31.87 | 57.70 | 43.51 | 51.68 |
| Liabilities | 7.31 | 8.67 | 5.50 | 3.38 | 2.43 | 4.44 | 2.57 | 13.00 | 5.55 | 5.73 |
| Book Value | 12.91 | 5.17 | 8.70 | 15.50 | 20.37 | 25.00 | 29.30 | 44.70 | 37.97 | 45.95 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
AIM ImmunoTech, Inc. |
| Country |
United States |
| Employees |
24 |
| CEO |
Thomas Kenwood Equels |
Stock Information
| Ticker Symbol |
AIM |
| Stock Exchange |
NYSE American |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NYSEAMERICAN: AIM |
Description
AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers and immune-deficiency disorders in the United States. The company's products include Alferon N Injection, an injectable formulation of natural alpha interferon to treat a category of genital warts, a sexually transmitted disease; and Ampligen, a drug of macromolecular ribonucleic acid molecule for the treatment of chronic fatigue syndrome. It is also developing Ampligen for the treatment of Hepatitis B and HIV, as well as patients with renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, urothelial, prostate, and pancreatic cancer. AIM ImmunoTech Inc. has research agreement with the Japanese National Institute of Infectious Diseases and Shionogi & Co., Ltd. to test its drug Ampligen as an adjuvant therapy for COVID-19, the new coronavirus infectious disease caused by SARS-CoV-2. The company was formerly known as Hemispherx Biopharma, Inc. and changed its name to AIM ImmunoTech Inc. in August 2019. AIM ImmunoTech Inc. was founded in 1966 and is headquartered in Ocala, Florida.